Compared to the low-risk group, the high-risk group had a higher percentage of history of thrombosis (58.8% vs. 0%, P < 0.001) and JAK2 mutation rate (85.9% vs. 66.7%, P = 0.005), and showed significantly increased levels of age (65 vs. 52 years, P < 0.001), white blood cells (10.7 vs. 8.5, P < 0.001), platelets (329 vs. 243, P < 0.001), neutrophils (6.8 vs. 5.4, P < 0.001), monocytes (0.42 vs. 0.34, P = 0.004), PHR (314.4 vs. 204.4, P < 0.001), NHR (6.32 vs. 4.89, P < 0.001), NLR (5.69 vs. 4.19, P < 0.001), MHR (0.39 vs. 0.30, P = 0.006), and SIRI (2.33 vs. 1.32, P < 0.001). This evidence concerns the gene JAK2 and deep vein thrombosis.